Turn Therapeutics Inc. TTRX
Set alert
At close · Oct 30
After hours · Oct 30, 5:33 PM ET
- YTD
- +164.72%
- 1 year
- +99.05%
- Open
- 10.45
- Prev close
- 10.72
- Mkt cap
- 316.74M
- Vol
- 137.07K
- Avg vol
- 105.53K
- EPS
- -0.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.60
- High
- 10.54
News
6 days ago benzinga.com
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Analysts upgraded SAFE, CNOB, LMT and more.
1 week ago benzinga.com
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
-
1 week ago benzinga.com
WBB Securities Upgrades Turn Therapeutics to Hold, Maintains Price Target to $10
WBB Securities analyst Karen Sterling upgrades Turn Therapeutics (NASDAQ:TTRX) from Sell to Hold and maintains the price target from $10 to $10.
1 week ago businesswire.com
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases,…
1 month ago benzinga.com
This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.
-
1 month ago benzinga.com
LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
-
1 month ago benzinga.com
WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target
WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sell and announces $10 price target.
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
1 month ago gurufocus.com
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin d
1 month ago businesswire.com
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D.
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious…
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
2 months ago gurufocus.com
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, toda
-
2 months ago benzinga.com
Turn Therapeutics Publishes Peer-Reviewed Research Of GX-03 In Life.
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory…
2 months ago businesswire.com
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases,…
2 months ago businesswire.com
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious…
3 months ago gurufocus.com
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today
3 months ago businesswire.com
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases,…
3 months ago marketbeat.com
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
Turn Therapeutics NASDAQ: TTRX outlined the final stage two design and data-driven expansion of its GX-03 phase II program in atopic dermatitis during an investor update call, saying the revised…
3 months ago benzinga.com
Why Is Turn Therapeutics Stock Trading Higher Today?
Turn Therapeutics, Inc. (NASDAQ:TTRX) on Tuesday said a planned interim analysis of its adaptive Phase 2 trial of GX-03 for atopic dermatitis has led to refinements in the study design and an…
3 months ago benzinga.com
Why Is Turn Therapeutics Stock Trading Higher Today?
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.
-
3 months ago benzinga.com
Turn Therapeutics Completes Comprehensive Interim Analysis Of Ongoing Adaptive Phase 2 Clinical Trial Evaluating GX-03 For Treatment Of Atopic Dermatitis
Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of…
3 months ago businesswire.com
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases,…
-
3 months ago benzinga.com
Turn Therapeutics To Present Data On Its Interim Analysis Of Its Current Adaptive Phase 2 Study Of GX-03 In Atopic Dermatitis
Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast…
3 months ago businesswire.com
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases,…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
5 months ago benzinga.com
Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic Dermatitis
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks…
5 months ago businesswire.com
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today…
5 months ago businesswire.com
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin…
5 months ago businesswire.com
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today…
5 months ago gurufocus.com
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today an
5 months ago businesswire.com
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today…
-
5 months ago benzinga.com
Turn Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate
Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 200 percent decrease over losses of…
5 months ago businesswire.com
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic…
6 months ago defenseworld.net
Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher – Should You Buy?
Turn Therapeutics Inc. (NASDAQ: TTRX - Get Free Report)'s share price traded up 6% during trading on Friday. The stock traded as high as $3.55 and last traded at $3.55. 15,975 shares traded hands…
6 months ago defenseworld.net
Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX)
Athersys (NASDAQ: ATHX - Get Free Report) and Turn Therapeutics (NASDAQ: TTRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two…
-
9 months ago benzinga.com
D. Boral Capital Maintains Buy on Turn Therapeutics, Maintains $8 Price Target
D. Boral Capital analyst Jason Kolbert maintains Turn Therapeutics (NASDAQ:TTRX) with a Buy and maintains $8 price target.
-
9 months ago benzinga.com
Turn Therapeutics Advances GX-03 Phase 2 Program, Expands Vaccine Pipeline; Targets Initial Commercial Revenue In 2026
Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026Appointment of Martin Dewhurst, a 30+ years McKinsey &…
-
10 months ago benzinga.com
D. Boral Capital Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $8
D. Boral Capital analyst Jason Kolbert initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $8.
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
Turn Therapeutics Enters Into Global Supply, Development, And License Agreement With Medline
Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has…
1 year ago benzinga.com
Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings
Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings
1 year ago benzinga.com
US Stocks Mixed; Nasdaq Falls Over 50 Points
US Stocks Mixed; Nasdaq Falls Over 50 Points
1 year ago benzinga.com
Stock Market Today: S&P 500, Nasdaq Futures Slip As Fed Minutes Signal Tariff-Related Uncertainty—PepsiCo, Delta, Levi Strauss In Focus (UPDATED)
Editor’s Note: The future prices of benchmark tracking ETFs were updated in the story. U.S. stock futures fell on Thursday following Wednesday’s mixed close. Futures of major benchmark indices were…
1 year ago benzinga.com
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
PepsiCo, Delta Air Lines And 3 Stocks To Watch Heading Into Thursday
Stock futures mixed, investor focus on PepsiCo, Costco, and Delta earnings. Turn Therapeutics surges, while Levi Strauss reports after bell.
1 year ago benzinga.com
Turn Therapeutics Shares Skyrocket 134% After Hours Following Nasdaq Debut
Turn Therapeutics' shares surged 134% in after-hours trading following its Nasdaq debut, despite a sharp decline during the regular session.